Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 117   

Articles published

JNJ 106.70 -0.18 (-0.17%)
price chart
Johnson & Johnson, Transposagen To Co-Develop CAR-T Therapy
Transposagen Biopharmaceuticals, Inc announced today that it has signed an agreement with Johnson & Johnson (NYSE:JNJ), under which it will be able to collaborate with the latter's Janssen biotech unit to develop the pipeline product, allogeneic ...
Transposagen Bio and J&J unit team up in cancer (JNJ)  Seeking Alpha
UPDATED: J&J jumps into hot CAR-T field with gene-editing experts at ...  FierceBiotech
Related articles »  
John J. Heldrich, former top executive at Johnson & Johnson and civic leader ...
NEW BRUNSWICK - John J. Heldrich, a retired Johnson & Johnson executive who went on to become a leader in New Brunswick's historic revitalization, died this morning at his home.
Johnson & Johnson May Settle 1000 More DePuy ASR Hip Claims for $250 M
On the heels of Johnson & Johnson's win this week in its Pinnacle Hip implant trial, the pharmaceutical giant may offer $250 million to settle lawsuits not included in its previous offer to settle thousands of DePuy ASR hip claims from last year ...
J&J May Pay $250 Million to Settle 1000 More Hip Claims  Bloomberg
Related articles »  
China's Red Tape Hurts Drug Market, CEOs Say
In a separate interview, Johnson & Johnson Chief Executive Alex Gorsky agreed, saying that it takes an average of eight years for drug approval in China, compared with four years in other markets.
Jim Cramer Weighs In On Johnson & Johnson And Toyota Motor  Benzinga
Johnson & Johnson (JNJ) Eyeing Expansion In China  Bidness ETC
Related articles »  
Johnson & Johnson to host innovation event at Cardiff's Life Sciences Hub
Johnson & Johnson Innovation joined the Life Sciences Hub Wales as a member in July 2014, after recognising opportunities to partner with the academic and entrepreneurial community to exchange ideas, research and develop medicines and equipment.
Johnson & Johnson's Partnership With Geron Emphasizes Its Push In Oncology
Johnson & Johnson has entered a partnership with Geron to develop its blood cancer treatment candidate, Imetelstat. The news sent the shares of Geron up by 40%, which means that for Geron's investors this is a big deal.
Should Johnson & Johnson Buy Medivation Inc.?
Johnson & Johnson (NYSE: JNJ ) is losing the battle for prostate cancer market share to the far smaller Medivation (NASDAQ: MDVN ) , but that may not mean that J&J should step up and acquire the company.
Related articles »  
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson JNJ -0.71% (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Johnson & Johnson Takes Care Of Both Consumers And Stockholders (JNJ)
Johnson & Johnson (NYSE:JNJ) might be a household name for consumers providing a wide range of products from Band-Aids to mouthwash, but their business extends far deeper than many know.
Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow
Johnson & Johnson (NYSE:JNJ) Synergy With Geron
Related articles »  
Johnson & Johnson, other firms in suit over alleged talcum powder cancer risk ...
TRENTON -- A number of companies -- including New Brunswick-based Johnson & Johnson and Sanofi of Bridgewater -- have been named in a federal lawsuit filed by a widower who says the companies failed to notify women that talcum powder has been ...
Related articles »